Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Operating Expenses (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Operating Expenses readings, the most recent being $159.2 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 0.72% to $159.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $733.3 million, a 24.56% increase, with the full-year FY2025 number at $733.3 million, up 24.56% from a year prior.
  • Operating Expenses hit $159.2 million in Q4 2025 for Tandem Diabetes Care, up from $157.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $239.3 million in Q1 2025 to a low of $76.5 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $138.4 million (2023), compared with a mean of $139.1 million.
  • Biggest five-year swings in Operating Expenses: surged 97.99% in 2023 and later crashed 35.29% in 2024.
  • Tandem Diabetes Care's Operating Expenses stood at $101.0 million in 2021, then skyrocketed by 31.99% to $133.3 million in 2022, then decreased by 3.71% to $128.4 million in 2023, then rose by 23.12% to $158.0 million in 2024, then rose by 0.72% to $159.2 million in 2025.
  • The last three reported values for Operating Expenses were $159.2 million (Q4 2025), $157.2 million (Q3 2025), and $177.7 million (Q2 2025) per Business Quant data.